Your Personalized Anti-Estrogen Therapy Plan

The Breast Cancer Index® (BCI™) Test provides personalized information that empowers you and your oncology care team to make optimal decisions regarding the length of your anti-estrogen treatment. When you can see the finish line, every day feels worth it.

Find Your Finish to Anti-Estrogen Therapy 
Get My BCI Test

About the Test

The BCI test provides two results to help you make a personalized decision about the length of your anti-estrogen therapy:

  1. A clear “yes” or “no” answer to whether an additional five years of anti-estrogen therapy is likely to reduce your risk of recurrence.
  2. Your individual percent risk of metastatic recurrence after the five year mark, if you take five years of anti-estrogen therapy versus ten.

Additional results may also be provided if your doctor orders the test earlier in your treatment or at diagnosis. These additional results provide your risk of metastatic recurrence over the 10 years following diagnosis to help your doctor personalize anti-estrogen therapy in the first 5 years of treatment. For postmenopausal women, this may help your doctor to further tailor your length of treatment, and for premenopausal women, this may help provide additional insight about whether the addition of ovarian function suppression may be avoided.

Explore the Report

The BCI test is the only genomic test recognized by leading oncology guidelines to predict which patients are likely to benefit from continuing anti-estrogen therapy after the first five years of treatment.1,2 

The Breast Cancer Index Test is Changing Care—For Good

The BCI test impacts decisions, helping you and your doctor to make personalized decisions about the appropriate length of anti-estrogen treatment. No more, no less. Following the BCI test results:

BCI Patient
45%

of patients changed their preference to either continue or not continue their anti-estrogen therapy.3

41%

of patients felt more comfortable with their decision.3

Healthcare providers changed anti-estrogen therapy recommendations for 40% of patients, either helping avoid unnecessary side effects or reducing the risk of a potential metastatic recurrence.3

The BCI test gives you and your doctor the information you need to make a personalized decision for you.

Resources Get the Test

“I finally feel like I’m done with cancer treatment.”

—Michelle*, Breast Cancer Survivor and BCI Patient

Women like Michelle found their finish to anti-estrogen therapy. Let stories like hers help you find yours.

Watch More
“I finally feel like I’m done with cancer treatment.”

Women like Michelle found their finish to anti-estrogen therapy. Let stories like hers help you find yours.

Watch More

*Michelle Beck is a patient ambassador for the Breast Cancer Index test. Statements reflect the speakers' own personal views and interpretations.

Breast Cancer Index Test Intended Uses and Limitations
The Breast Cancer Index (BCI) test is a polymerase chain reaction (PCR) based gene expression test which analyses two gene expression signatures from formalin-fixed, paraffin embedded (FFPE) tissue block or unstained sections on glass slides via macrodissection. The gene expression signatures include the Molecular Grade Index (MGI), a five-gene signature, and the HOXB13/IL17BR (H/I), a two-gene ratio signature. The test is indicated for use in women diagnosed with early-stage hormone receptor-positive (HR+), lymph node negative (N0) or lymph node-positive (N1; 1-3 positive nodes) invasive breast cancer. The BCI test provides a quantitative estimate of overall (years 0-10) and late (years 5-10) distant recurrence risk and informs the likelihood of endocrine therapy benefit for women who are distant recurrence-free.

BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings. This test was developed, and its performance characteristics determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes and should not be regarded as experimental or investigational. How this information is used to guide patient care is the responsibility of the treating provider. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.5.2025. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed October 28, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 2. Andre F, et al. J Clin Oncol. 2022;40(16):1816-1837. Referenced with permission from the American Society of Clinical Oncology (ASCO®) Clinical Practice Guideline Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer. © American Society of Clinical Oncology. 2025. All rights reserved. To view the most recent and complete version of the guideline, go online to https://ascopubs.org/jco/special/guidelines [ascopubs.org]. ASCO makes no warranties of any kind whatsoever regarding their content, use of application and disclaims any responsibility for their application or use in any way. 3. Sanft TB, et al. J Natl Compr Canc Netw. 2024; 22(2):99-107.